• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Drug discovery - Articles and news items

BioTek Introduces 2nd Generation Cytation Imaging Reader

BioTek introduces 2nd Generation Cytation Imaging Reader

Supplier news / 14 October 2015 / BioTek

BioTek is excited to introduce the new Cytation™ 5 Cell Imaging Multi-Mode Reader…

BioTek Introduces Synergy Neo2 High Performance Multi-Mode Microplate Reader

BioTek introduces Synergy Neo2 high performance Multi-Mode Microplate Reader

Supplier news / 14 October 2015 / BioTek

BioTek introduces Synergy Neo2 high performance Multi-Mode Microplate Reader…

Mirus Bio: Development and Optimization of CHOgro® Transient Expression Technologies for High Titer Antibody Production in Suspension CHO Cells

Whitepaper: Development and optimization of CHOgro® transient expression technologies for high titer antibody production in suspension CHO cells

Whitepapers, Z Homepage promo / 1 October 2015 / Mirus Bio

During early stage drug development, quickly obtaining relevant candidate proteins through transient transfection can accelerate drug discovery…


Webinar: Biased ligands in Drug Discovery – the case of TRV027

Webinars, Z Homepage promo / 1 July 2015 / Cisbio Bioassays & Trevena, Inc.

TRV027 is a biased ligand; the in vitro profile and its translation into in vivo pharmacology is discussed during this webinar.

Oxford Global

Oxford Global Conferences received excellent feedback from the 2014 Drug Discovery USA Congress

Industry news / 8 January 2015 / Oxford Global Conferences

Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA…

drug discovery & drug development

Imaging for decision-making in drug discovery and early development

Issue 6 2014 / 23 December 2014 / Paul McCracken & Stephen Krause

In this review, we highlight a few of the ways in which Eisai is attempting to address the research and development bottleneck by adding fit-for-purpose imaging biomarkers to discovery and early development programs for decision making…

AMSBIO logo 200x200

3D Cell-Based Models for Regenerative Medicine and Drug Discovery

News, Supplier news / 18 November 2013 / AMSBIO

Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery…


Proteases: How naturally occurring inhibitors can facilitate small molecule drug discovery for cysteine proteases

Issue 4 2013, Proteomics / 20 August 2013 / Sheraz Gul, Vice President and Head of Biology, European ScreeningPort GmbH

Cysteine proteases are expressed ubiquitously in the animal and plant kingdom and are thought to play key roles in maintaining homeostasis. The aberrant function of cysteine proteases in humans are known to lead to a variety of epidermal disease states such as inflammatory skin disease. In marked contrast, the serine proteases have been most widely implicated in disease states, including hypertension, periodontisis, AIDS, thrombosis, respiratory disease, pancreatitis and cancer, and a number of their inhibitors have been approved for clinical use.

Raman spectroscopy: an enabling tool for accelerating pharmaceutical discovery to development

Raman spectroscopy: an enabling tool for accelerating pharmaceutical discovery to development

Issue 4 2013, Raman Spectroscopy / 20 August 2013 / Chanda R. Yonzon, Atul Karande, Sai P. Chamarthy and Brent A. Donovan (Merck & Co. Inc)

Raman spectroscopy has emerged as the preeminent analytical tool for a number of applications within drug discovery and development. Advances in the instrumentation, sensor fabrication and data analysis have enabled the wider acceptance of Raman spectroscopy. In discovery, Raman spectroscopy is used to elucidate structural activity relationships and to optimise reaction conditions and associated parameters (such as polymorph and formulation screening) that impact scale-up required for the transfer of drug compounds from discovery to development.

Cell based label-free assays in GPCR drug discovery

GPCRs: Cell based label-free assays in GPCR drug discovery

Drug Targets, Issue 4 2013 / 20 August 2013 / Niklas Larsson, Linda Sundström, Erik Ryberg and Lovisa Frostne (AstraZeneca)

G protein-coupled receptors are one of the major classes of therapeutic targets for a broad range of diseases. The most commonly used assays in GPCR drug discovery measure production of second messengers such as cAMP or IP3 that are the result of activation of individual signalling pathways. Such specific assays are unable to provide a holistic view of the cell response after GPCR activation. This is now changing as label-free technologies and assays on whole cells have been developed that are unbiased towards the specific downstream pathways and capture the integrated cell response. In this mini-review, we focus on the application of one of these technologies, namely resonant waveguide grating (RWG) for measurements of dynamic mass redistribution (DMR) in intact cells upon GPCR activation. Since the technology is sensitive and non-invasive, it is applicable to most cell types, including primary cells with native receptor expression levels. We discuss how DMR assays have become an important component of GPCR drug discovery screening cascades and may have the potential to improve the ability to predict if compounds will be efficacious in vivo.


Collaboration to accelerate drug discovery in cardiac disease announced

Industry news, News / 19 March 2013 / InvivoSciences Inc.

Torrey Pines Institute for Molecular Studies and InvivoSciences collaborate to accelerate drug discovery in cardiac disease…

Cancer Research UK drug launched in its first clinical trial

Future trends in drug discovery technology

Drug Discovery, Issue 6 2012 / 18 December 2012 / Terry McCann, TJM Consultancy

The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion. Herper observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of biology. While the objectives of drug discovery don’t change, the methods and techniques by which pharmaceutical companies, biotechs and academia discover new drugs are evolving at a significant pace – and they need to. Drug discovery scientists are all aiming to identify compounds and candidate drugs with ‘good’ properties that are safe and efficacious, as quickly and cheaply as possible. The standard approach of the last 20 years has been to identify a single molecule disease target, and then to identify a compound that interacts with and modulates this target with high specificity. However, there is now a growing realisation that this ‘one target – one drug’ approach doesn’t work well, and that screening huge libraries of compounds against one particular property of an isolated target is an inefficient way to discover potential drugs. Much of the innovation currently seen in drug discovery methodologies seeks to access and integrate more information – about targets, compounds, and disease phenotypes – to enable a more comprehensive and holistic approach to discovering ‘good’ drug candidates. This article does not try to crystal ball-gaze deep into the future, but rather to identify those trends in the adoption of new technologies and approaches that are gaining traction now, and that can be expected to become more prevalent in the next two to three years…


Webinar: Fit-for-Purpose Miniature NIR Spectroscopy for Solid Dosage ManufacturingREGISTER TO WATCH
+ +